A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome.
Hammond TC, Purbhoo MA, Kadel S, Ritz J, Nikiforow S, Daley H, Shaw K, van Besien K, Gomez-Arteaga A, Stevens D, Ortuzar W, Michelet X, Smith R, Moskowitz D, Masakayan R, Yigit B, Boi S, Soh KT, Chamberland J, Song X, Qin Y, Mishchenko I, Kirby M, Nasonenko V, Buffa A, Buell JS, Chand D, van Dijk M, Stebbing J, Exley MA.
Hammond TC, et al. Among authors: nikiforow s.
Nat Commun. 2024 Feb 6;15(1):974. doi: 10.1038/s41467-024-44905-z.
Nat Commun. 2024.
PMID: 38321023
Free PMC article.
Clinical Trial.